Estrogen-receptor positive breast cancer

This early-stage trial tests a new drug, GDC-0587, alone or with another drug (giredestrant), in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after prior CDK4/6 inhibitor therapy. The study aims to find safe doses and check for side effects.…

This early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…

This study tested a new drug called amcenestrant against standard hormone therapies in 367 people with advanced ER+/HER2- breast cancer. The goal was to see if it could slow cancer growth better than current options. The trial was stopped early, but results help guide future trea…

This early-phase trial tested a combination of two drugs—infigratinib (a targeted therapy) and tamoxifen (a hormone therapy)—in people with a specific type of advanced breast cancer (hormone receptor-positive, HER2-negative, with FGFR gene changes). The goal was to find a safe do…

This study tested a new oral drug called amcenestrant for postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). The goal was to find safe doses and see if it works alone or with other drugs. The trial was stopped early, but the results help researchers u…

This study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…

This Phase 2 study tested two doses of amcenestrant, a new oral drug that blocks estrogen receptors, against letrozole, a standard hormone therapy, in 105 postmenopausal women with ER-positive, HER2-negative breast cancer. The goal was to see if amcenestrant could better reduce t…

This phase 3 trial tested whether a new drug called amcenestrant (which blocks estrogen) combined with palbociclib could help people with advanced ER+/HER2- breast cancer live longer without their cancer growing. Over 1,000 participants who had not yet received treatment for adva…

This study tested a special PET/CT scan using a radioactive tracer called FES to see estrogen receptor activity in women with advanced, hormone-resistant breast cancer. The goal was to see if the scan could predict how well a new hormone therapy would work. Only 6 people were enr…